Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of two pharmaceutical products: Glycyrrhizic Acid Ammonium and Sodium Ferulate Injection [1] Group 1: Product Approvals - The company has been granted a "Chemical Raw Material Drug Re-registration Approval Notice" for Glycyrrhizic Acid Ammonium, which is a raw material used for producing Glycyrrhizic Acid Ammonium Injection [1] - Additionally, the company received a "Drug Re-registration Approval Notice" for Sodium Ferulate Injection, which is used as an auxiliary treatment for ischemic cardiovascular and cerebrovascular diseases [1]

Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. has received approval from the Chongqing Municipal Drug Administration for the re-registration of one chemical raw material (Dipotassium Glycyrrhizinate) and one drug (Sodium Ferulate Injection) [1] Group 1: Product Approvals - The re-registration approval includes a notification for the chemical raw material Dipotassium Glycyrrhizinate, which is used for the production of Glycyrrhizinate Injection [1] - The Sodium Ferulate Injection is indicated for the auxiliary treatment of ischemic cardiovascular and cerebrovascular diseases [1] Group 2: Impact on Operations - The re-registration approval will ensure the normal production and sales of the related drugs [1] - The company will strictly control product quality [1] - However, there is no significant short-term impact on the company's operating performance [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of two pharmaceutical products: Glycyrrhizic Acid Dipotassium Salt and Sodium Ferulate Injection [1] Group 1: Product Approvals - The company has been granted a re-registration approval notice for Glycyrrhizic Acid Dipotassium Salt, which is a raw material used for producing Glycyrrhizic Acid Dipotassium Salt Injection [1] - The Sodium Ferulate Injection, which is used as an auxiliary treatment for ischemic cardiovascular and cerebrovascular diseases, has also received re-registration approval [1]

Group 1 - The company, Chongqing Huason Pharmaceutical Co., Ltd., will participate in the "2025 Investor Online Collective Reception Day" and semi-annual performance briefing on September 25, 2025 [1][2] - The event aims to enhance investor relations management and promote high-quality development of listed companies in the Chongqing area [1] - Key company representatives, including the Deputy General Manager and the Chief Financial Officer, will engage in online communication with investors during the event [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-075 重庆华森制药股份有限公司 届时，公司副总经理及董事会秘书游雪丹女士、财务总监彭晓燕女士及相关人 员将参与本次活动，并通过网络在线交流形式，就投资者所关心的问题，与投资者 进行"一对多"形式的在线沟通。欢迎广大投资者踊跃参与。 特此公告 重庆华森制药股份有限公司 董事会 2025 年 9 月 18 日 关于参加重庆辖区上市公司 2025 年投资者网上集体接待日 暨半年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 为进一步提高辖区上市公司投资者关系管理水平，促进公司完善公司治理，助 力上市公司高质量发展，在重庆证监局指导下，重庆上市公司协会联合深圳市全景 网络有限公司举办"重庆辖区上市公司 2025 年投资者网上集体接待日暨半年度业 绩说明会活动"。本次活动将于 2025 年 9 月 25 日（星期四）15:00～17:00 举行， 投资者可以登录全景路演（http://rs.p5w.net）进入重庆华森制药股份有限公司 （以下简称"公司"）互动平台参与交流。 ...

一、变更内容 1.延续受托生产有效期：重庆中创科医药有限公司委托生产的注射用艾司奥美 拉唑钠（国药准字：H20243180），受托生产有效期延长至 2026 年 11 月 22 日； 2.延续受托生产有效期（仅限注册申报使用）：四川海梦智森生物制药有限公 司委托生产的维生素 D 滴剂（规格：每粒含维生素 D3 400 单位、每粒含维生素 D3 800 单位），受托生产有效期延长至 2030 年 6 月 29 日。 二、变更后的《药品生产许可证》具体内容 | 企 | 业 | | 名 | 称：重庆华森制药股份有限公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 许 | 可 | 证 | 编 | 号：渝 20150018 | | | | | 社 | 会 | 信 | 用 代 | 码：915002262038944463 | | | | | 分 | | 类 | | 码：AhzyBhzChDh | | | | | 注 | 册 | | 地 | 址：重庆市荣昌区工业园区 | | | | | 法 | 定 | 代 | 表 | 人：游洪涛 | | | | | ...

Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 442 million, an increase of 5.76% compared to the same period last year [3] - The net profit attributable to shareholders reached CNY 53.95 million, up 14.27% year-on-year [3] - The basic and diluted earnings per share increased by 14.24% compared to the previous year [3] Key Growth Drivers - Revenue growth was driven by a 29.45% increase in revenue from approved generic drugs and successful bidding in centralized procurement [3] - Steady growth in the revenue of five key traditional Chinese medicine products, which increased by 3.52% year-on-year [3] - Cost control measures and a decrease in raw material prices contributed to profit growth [3] Research and Development - R&D investment in the first half of 2025 was CNY 40.50 million, a year-on-year increase of 29.33%, accounting for 9.17% of revenue [7] - The company has 7 innovative drug projects in the pipeline, targeting various cancers and autoimmune diseases [8] - A total of 8 new compound patents were applied for in the first half of 2025, with 3 granted [8] Product Development and Market Strategy - The company has four self-developed special medical foods, with the first product receiving regulatory approval [9] - The sales strategy remains stable, focusing on public hospitals, which account for approximately 70% of sales [12][13] - The company is expanding its market presence through digital marketing and e-commerce platforms [9] Shareholder Returns - The company distributed CNY 0.35 per 10 shares to shareholders, totaling CNY 14.62 million [14] - The profit distribution plan was approved and implemented in September 2025 [14] Governance and Internal Control - The company has established a comprehensive internal control system, which has been positively evaluated by external auditors [11][15] - Continuous improvements to governance structures and compliance with legal regulations are prioritized [15]

Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. has received the approval notice for the supplementary application of Jian'er Xiaoshi Oral Liquid, marking the company as the holder of the drug marketing license, which is expected to enhance its product pipeline and expand its retail market presence [1][4]. Group 1: Drug Information - Jian'er Xiaoshi Oral Liquid is indicated for strengthening the spleen and stomach, regulating qi, and aiding digestion, particularly for children suffering from poor appetite and digestive issues due to irregular eating habits [2][3]. - The recommended dosage is 5-10 milliliters for children under 3 years old and 10-20 milliliters for those over 3 years, administered twice daily [2]. Group 2: Market Context - The pediatric traditional Chinese medicine market has been steadily growing, with sales reaching 18.3 billion yuan in 2024. Public hospitals account for 50.1% of sales, while retail pharmacies contribute 37% [3]. - Pediatric appetite disorder medications dominate the pediatric traditional Chinese medicine market, with Jian'er Xiaoshi Oral Liquid being a common choice due to its safety and palatable taste [3]. Group 3: Company Impact - The approval of Jian'er Xiaoshi Oral Liquid will enrich the company's product offerings and enhance its sales in the pediatric digestive field, contributing to sustainable development [4]. - The company plans to initiate marketing efforts promptly following the approval [4].

Core Viewpoint - Huason Pharmaceutical (002907) has successfully completed the change of drug production license holder for its product Jianer Xiaoshi Oral Liquid, marking a significant regulatory milestone for the company [1] Company Summary - The company announced on September 5 that it received the approval notice from the National Medical Products Administration regarding the supplementary application for the product [1] - The completion of the license holder change indicates that Huason Pharmaceutical is now the legal holder of the drug's marketing authorization [1]

重庆华森制药股份有限公司 关于公司获得健儿消食口服液药品补充申请批准通 证券代码：002907 证券简称：华森制药 公告编号：2025-073 知书暨成为药品上市许可持有人的公告 一、药品基本信息 （一）健儿消食口服液 | 药 | | 品 | | 名 | 称：健儿消食口服液 | | --- | --- | --- | --- | --- | --- | | 剂 | | | | | 型：合剂 | | 注 | | 册 | | 分 | 类：中药 | | 规 | | | | | 格：每支装 10ml | | 受 | | | 理 | | 号：CYZB2501707 | | 通 | | 知 | 书 | 编 | 号：2025B03991 | | 原 | 药 | 品 | 批 | 准 文 | 号：国药准字 Z41021020 | 申 请 内 容：其他：申请进行药品上市许可持有人主体变更，将本 品上市许可持有人由"河南灵佑药业股份有限公司" 变更为"重庆华森制药股份有限公司"。 审 批 结 论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品此次申请事项符合药品注册的有关要求， 同意按照《药品上市后变更管理办法（试行） ...